These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23316991)

  • 81. Role of emerging new technologies.
    Garg SK
    Diabetes Technol Ther; 2008 Oct; 10(5):413-4. PubMed ID: 18715219
    [No Abstract]   [Full Text] [Related]  

  • 82. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.
    Yeh HC; Brown TT; Maruthur N; Ranasinghe P; Berger Z; Suh YD; Wilson LM; Haberl EB; Brick J; Bass EB; Golden SH
    Ann Intern Med; 2012 Sep; 157(5):336-47. PubMed ID: 22777524
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [When tablets are no longer enough. Which insulin for type 2 diabetic patients?].
    MMW Fortschr Med; 2002 Sep; 144(38):58. PubMed ID: 12395711
    [No Abstract]   [Full Text] [Related]  

  • 84. Target attainment through algorithm design during intravenous insulin infusion.
    Devi R; Zohra T; Howard BS; Braithwaite SS
    Diabetes Technol Ther; 2014 Apr; 16(4):208-18. PubMed ID: 24354344
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [A simple regimen only lasts a short time].
    Einecke D
    MMW Fortschr Med; 2007 Oct; 149(40):12-4. PubMed ID: 18018501
    [No Abstract]   [Full Text] [Related]  

  • 86. [An update on multiple insulin injection therapy in type 1 and 2 diabetes].
    Varanauskiene E; Varanauskaite I; Ceponis J
    Medicina (Kaunas); 2006; 42(9):770-9. PubMed ID: 17028476
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Insulin glargine clinical trials.
    White JR
    Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
    [No Abstract]   [Full Text] [Related]  

  • 88. Evaluation of diabetic patients after three month use of continuous subcutaneous insulin infusion, dispensed by a protocolled form at outpatient reference clinic of Taguatinga Regional Hospital.
    Miranda LG; Pedrosa HC; Falleiros RK; Oliveira Rde M; Tolentino M; Casulari LA
    Arch Endocrinol Metab; 2015 Feb; 59(1):23-8. PubMed ID: 25926110
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Are individuals with diabetes seeing better?: a long-term epidemiological perspective.
    Klein R; Klein BE
    Diabetes; 2010 Aug; 59(8):1853-60. PubMed ID: 20668290
    [No Abstract]   [Full Text] [Related]  

  • 90. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
    Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
    Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS).
    New JP; Ajjan R; Pfeiffer AF; Freckmann G
    Diabet Med; 2015 May; 32(5):609-17. PubMed ID: 25661981
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c.
    Retnakaran R; Hochman J; DeVries JH; Hanaire-Broutin H; Heine RJ; Melki V; Zinman B
    Diabetes Care; 2004 Nov; 27(11):2590-6. PubMed ID: 15504991
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [When injectable diabetes therapy becomes necessary. Insulin or GLP-1 analogs?].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Jan; 153(1-2):14. PubMed ID: 24761480
    [No Abstract]   [Full Text] [Related]  

  • 94. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
    Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Emerging diabetes therapies and technologies.
    Moser EG; Morris AA; Garg SK
    Diabetes Res Clin Pract; 2012 Jul; 97(1):16-26. PubMed ID: 22381908
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19.
    Riahi S; Sombra LRS; Lo KB; Chacko SR; Neto AGM; Azmaiparashvili Z; Patarroyo-Aponte G; Rangaswami J; Anastasopoulou C
    Endocr Res; 2021; 46(2):45-50. PubMed ID: 33275067
    [No Abstract]   [Full Text] [Related]  

  • 97. Insulin therapy today. Focusing on the basal-bolus balance.
    McDonald K
    Adv Nurse Pract; 2003 Jul; 11(7):40-4; qiuz 44-5. PubMed ID: 12886737
    [No Abstract]   [Full Text] [Related]  

  • 98. The poor children of the poor: Coping with diabetes control in a resource-poor setting.
    De Villiers FP
    S Afr Med J; 2015 Apr; 105(5):397-9. PubMed ID: 26242670
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Inappropriate respect for patient fears. Physicians wait too long with insulin].
    MMW Fortschr Med; 2004 Jun; 146(24):53. PubMed ID: 15366500
    [No Abstract]   [Full Text] [Related]  

  • 100. The effects of correction insulin and basal insulin on inpatient glycemic control.
    Johnston JA; Van Horn ER
    Medsurg Nurs; 2011; 20(4):187-93. PubMed ID: 21941930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.